Tiburio Therapeutics
Cambridge
About Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $31.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2019)
- Website: tiburio.com
- Phone: +1 (617) 231-6050
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tiburio-therapeutics-109589 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.